Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen

DB10342ApprovedInvestigationalVaccinesInactivated Haemophilus Influenzae B Vaccine

Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen is a vaccine containing outer membrane antigen extracted from Haemophilus influenzae.

First approval
United States, 1989 · European Union, 2021
Also known as
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine
Brand names
  • Infanrix Hexa
  • Pedvaxhib
  • Vaxelis

Resolves to

Compound
UNIILUY6P8763W
Clinical / RWD
RxNorm798444

What you can answer from here — as of April 02, 2025

17Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
47Marketed productsAcross 5 countries and 9 labellers
Sign in

Which other approved drugs treat the same conditions as Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In